[go: up one dir, main page]

WO2000067738A3 - Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires - Google Patents

Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires Download PDF

Info

Publication number
WO2000067738A3
WO2000067738A3 PCT/US2000/012339 US0012339W WO0067738A3 WO 2000067738 A3 WO2000067738 A3 WO 2000067738A3 US 0012339 W US0012339 W US 0012339W WO 0067738 A3 WO0067738 A3 WO 0067738A3
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosine kinase
protein tyrosine
prophylactic
kinase pathway
therapeutic treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/012339
Other languages
English (en)
Other versions
WO2000067738A2 (fr
Inventor
Juan Eugene De Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Priority to CA2373178A priority Critical patent/CA2373178C/fr
Priority to EP00932108A priority patent/EP1178791A2/fr
Priority to MXPA01011344A priority patent/MXPA01011344A/es
Priority to AU49884/00A priority patent/AU774495B2/en
Priority to JP2000616765A priority patent/JP4920134B2/ja
Publication of WO2000067738A2 publication Critical patent/WO2000067738A2/fr
Publication of WO2000067738A3 publication Critical patent/WO2000067738A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)

Abstract

L'invention concerne un procédé de traitement prophylactique et thérapeutique pour la dégénérescence maculaire liée au vieillissement, ainsi que des procédés de traitement prophylactique et thérapeutique pour les complications exsudatives et atrophiques de ladite dégénérescence. Ces procédés consistent à administrer un inhibiteur de trajet de protéine tyrosine kinase à un animal, du type mammifère, en particulier à un être humain, en quantité suffisante pour les besoins du traitement prophylactique ou thérapeutique de la dégénérescence ou des complications considérées, respectivement. L'invention concerne en outre un procédé de traitement prophylactique et thérapeutique pour la dégénérescence rétinienne, un procédé de traitement prophylactique et thérapeutique pour la dégénérescence choroïdienne, et un procédé de traitement prophylactique et thérapeutique pour l'épaississement de la membrane de Bruch. Ces procédés consistent à administrer un inhibiteur de trajet de protéine tyrosine kinase à un animal, du type mammifère, en particulier à un être humain, en quantité suffisante pour les besoins du traitement prophylactique ou thérapeutique de la dégénérescence maculaire, rétinienne ou choroïdienne, ou bien de l'épaississement de la membrane de Bruch, respectivement. De préférence, cet inhibiteur est de la génistéine ou bien un analogue ou un promédicament correspondant, ou encore un sel pharmaceutiquement acceptable de l'un quelconque de ces produits.
PCT/US2000/012339 1999-05-07 2000-05-05 Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires Ceased WO2000067738A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2373178A CA2373178C (fr) 1999-05-07 2000-05-05 Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires
EP00932108A EP1178791A2 (fr) 1999-05-07 2000-05-05 Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires
MXPA01011344A MXPA01011344A (es) 1999-05-07 2000-05-05 El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares.
AU49884/00A AU774495B2 (en) 1999-05-07 2000-05-05 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
JP2000616765A JP4920134B2 (ja) 1999-05-07 2000-05-05 眼障害の処置におけるプロテインチロシンキナーゼ経路インヒビターの使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13311299P 1999-05-07 1999-05-07
US35044099A 1999-07-09 1999-07-09
US60/133,112 1999-07-09
US09/350,440 1999-07-09

Publications (2)

Publication Number Publication Date
WO2000067738A2 WO2000067738A2 (fr) 2000-11-16
WO2000067738A3 true WO2000067738A3 (fr) 2001-08-23

Family

ID=26831056

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012339 Ceased WO2000067738A2 (fr) 1999-05-07 2000-05-05 Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires

Country Status (6)

Country Link
EP (1) EP1178791A2 (fr)
JP (1) JP4920134B2 (fr)
AU (1) AU774495B2 (fr)
CA (1) CA2373178C (fr)
MX (1) MXPA01011344A (fr)
WO (1) WO2000067738A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826276A1 (fr) * 2001-06-20 2002-12-27 Raouf Rekik Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
US12035973B2 (en) 2018-01-25 2024-07-16 Osaka University Method for detecting stressed state and stress detection apparatus
CN114931574A (zh) * 2022-06-14 2022-08-23 深圳爱尔眼科医院 一种铁死亡抑制剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040090A1 (fr) * 1997-03-14 1998-09-17 The Regents Of The University Of California Methodes d'inhibition de cytotoxicite bacterienne
WO1999045920A2 (fr) * 1998-03-13 1999-09-16 Johns Hopkins University School Of Medicine Traitement de la retinopathie diabetique ou des inflammations oculaires au moyen d'un inhibiteur des tyrosine-kinases tel que la genisteine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09316000A (ja) * 1996-05-31 1997-12-09 Toagosei Co Ltd 血管新生抑制用ワクチン
DE69734290T2 (de) * 1996-11-05 2006-07-06 The Children's Medical Center Corp., Boston Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
CA2303830A1 (fr) * 1997-09-26 1999-04-08 Merck & Co., Inc. Nouveaux inhibiteurs de l'angiogenese

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040090A1 (fr) * 1997-03-14 1998-09-17 The Regents Of The University Of California Methodes d'inhibition de cytotoxicite bacterienne
WO1999045920A2 (fr) * 1998-03-13 1999-09-16 Johns Hopkins University School Of Medicine Traitement de la retinopathie diabetique ou des inflammations oculaires au moyen d'un inhibiteur des tyrosine-kinases tel que la genisteine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CASAGRANDE F. ET AL: "G1 phase arrest by the phosphatidylinositol 3-kinase inhibitor LY 294002 is correlated to up-regulation of p27(Kip1) and inhibition of G1 CDKs in choroidal melanoma cells.", FEBS LETTERS, (6 FEB 1998) 422/3 (385-390)., XP000971946 *
FAURE VIOLAINE ET AL: "Tyrosine kinase inhibitors and antioxidants modulate NF-kappaB and NOS-II induction in retinal epithelial cells.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 275, no. 1 PART1, July 1998 (1998-07-01), pages C208 - C215, XP000978431, ISSN: 0002-9513 *
HAYASHI A ET AL: "Genistein, a protein tyrosine kinase inhibitor, ameliorates retinal degeneration after ischemia-reperfusion injury in rat.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 38, no. 4 PART 1-2, 1997, Annual Meeting of the Association for Research in Vision and Ophthalmology, Parts 1-2;Fort Lauderdale, Florida, USA; May 11-16, 1997, pages S101, XP000978471, ISSN: 0146-0404 *
YOON H.S. ET AL: "Genistein produces reduction in growth and induces apoptosis of rat RPE-J cells.", CURRENT EYE RESEARCH, (2000) 20/3 (215-224)., XP000978532 *

Also Published As

Publication number Publication date
CA2373178C (fr) 2013-07-02
CA2373178A1 (fr) 2000-11-16
JP4920134B2 (ja) 2012-04-18
AU774495B2 (en) 2004-07-01
MXPA01011344A (es) 2004-06-03
WO2000067738A2 (fr) 2000-11-16
JP2002544159A (ja) 2002-12-24
EP1178791A2 (fr) 2002-02-13
AU4988400A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
CA2321560A1 (fr) Traitement de la retinopathie diabetique ou des inflammations oculaires au moyen d'un inhibiteur des tyrosine-kinases tel que la genisteine
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
Gros Spasticity—clinical classification and surgical treatment
WO1998010767A3 (fr) Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs
NO970517D0 (no) Topiske oftalmiske formuleringer inneholdende doxepinderivater for behandling av öyenallergisykdommer
EP2514420A3 (fr) Utilisation de rapamycine pour le traitement ou la prévention de la dégénération maculaire liée à l'âge
CA2502437A1 (fr) Procede et composition contenant du latanoprost destines au traitement de l'hypertension oculaire et d'un glaucome
WO2006071548A3 (fr) Analogues d'aminopyrazine servant a traiter le glaucome et d'autres maladies ou etats medies par rho kinase
HK1040185A1 (zh) 用緩釋皮質甾類治療和/或預防視網膜疾病的方法
CA2213833A1 (fr) Antagonistes de facteurs de croissance des cellules endotheliales vasculaires
PL373863A1 (en) Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
CA2265839A1 (fr) Manchons dotes de noeuds pour dispositifs prothetiques transcutanes ou intracorporels
EP1074258A3 (fr) Méthodes et compositions pour le traitement des maladies et des affections oculaires
CA2582316A1 (fr) Utilisation d'inhibiteurs de jun n-terminal kinases pour le traitement de la retinopathie glaucomateuse et de maladies oculaires
CA2262268C (fr) Methode pour traiter l'impuissance causee par des lesions a la moelle epiniere
WO2000067738A3 (fr) Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires
WO2002047673A3 (fr) Methodes et compositions pour le traitement d'etats pathologiques associes a la neovascularisation
WO2002051379A3 (fr) Aerosol nasal thixotropique
WO2002013805A3 (fr) Procede pour traiter des troubles neurodegeneratifs de la retine et de la papille optique
EP1037622A4 (fr) Derives de la taurine pour le traitement de troubles ophtalmiques
WO2005102303A3 (fr) Antiprostaglandines pour le traitement de pathologies oculaires
AU6418296A (en) Aromatic acid diamides with antigastrin activity, a method for their preparation and their pharmaceutical use
EP1482922A4 (fr) Agents pour une administration corneenne ou intrastromale pour traiter ou empecher les troubles oculaires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 49884/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2373178

Country of ref document: CA

Ref country code: CA

Ref document number: 2373178

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 616765

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011344

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000932108

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000932108

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 49884/00

Country of ref document: AU